Company profile
ProMIS Neurosciences, Inc.
NASDAQ: PMN · Healthcare · Biotechnology
Canadian filerHQ Toronto, ONCIK 0001374339Reports USD
#1 of 1,422 Healthcare companies by revenue
EA Score
——FH 29DQ —GM —SS 52
v0.1 · 35/100 weight · pillars only
↑ listing tenure, Altman-Z · ↓ return on assets, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$39.7M
Employees
11
as of 2026-08-21
Market cap
$19.5M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$39.7M-$39.7M2025
Operating income-$40.2M-$40.2M2025
Total assets$9.2M$9.2M2025
Liabilities$10.4M$10.4M2025
Equity-$1.3M-$1.3M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is ProMIS Neurosciences, Inc.’s financial profile?
ProMIS Neurosciences, Inc. earned -$39.7M in FY2025 net income.
Peers · Healthcare
Quantum BioPharma Ltd.——Werewolf Therapeutics, Inc.——Cellectar Biosciences, Inc.——ImpediMed Limited——Optimi Health Corp.——Akari Therapeutics, Plc——Key facts
CEONeil K. Warma
SectorHealthcare
IndustryBiotechnology
HeadquartersToronto, ON
ExchangeNASDAQ: PMN
Employees11
IPO date2007-01-10
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.